[
  {
    "path": "hema/09-30-2022/",
    "title": "Fri Sep 30 2022",
    "description": "97 articles - From Friday Sep 23 2022 to Friday Sep 30 2022",
    "author": [],
    "date": "2022-09-30",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nMiscellaneous\r\nLetters&Replies\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#ggzpdjetud .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#ggzpdjetud .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#ggzpdjetud .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ggzpdjetud .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#ggzpdjetud .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#ggzpdjetud .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#ggzpdjetud .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#ggzpdjetud .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ggzpdjetud .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#ggzpdjetud .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#ggzpdjetud .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#ggzpdjetud .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#ggzpdjetud .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#ggzpdjetud .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ggzpdjetud .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#ggzpdjetud .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#ggzpdjetud .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ggzpdjetud .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#ggzpdjetud .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#ggzpdjetud .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#ggzpdjetud .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#ggzpdjetud .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#ggzpdjetud .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#ggzpdjetud .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#ggzpdjetud .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#ggzpdjetud .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#ggzpdjetud .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    J Hematol Oncol\r\n    Evidence-based expert consensus on the management of primary central nervous system lymphoma in China. \r\nPatients with suspected primary vitreoretinal lymphoma (PVRL) should be diagnosed by vitreous biopsy. PVRL or PCNSL patients with concurrent VRL can be treated with combined systemic and local therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#cftgdckues .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#cftgdckues .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#cftgdckues .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#cftgdckues .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#cftgdckues .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#cftgdckues .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#cftgdckues .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#cftgdckues .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#cftgdckues .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#cftgdckues .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#cftgdckues .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#cftgdckues .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#cftgdckues .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#cftgdckues .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#cftgdckues .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#cftgdckues .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#cftgdckues .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#cftgdckues .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cftgdckues .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#cftgdckues .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#cftgdckues .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#cftgdckues .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#cftgdckues .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#cftgdckues .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#cftgdckues .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#cftgdckues .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#cftgdckues .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Haematologica\r\n    Comment on: Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#oeikiyklay .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#oeikiyklay .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#oeikiyklay .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#oeikiyklay .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#oeikiyklay .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#oeikiyklay .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#oeikiyklay .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#oeikiyklay .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#oeikiyklay .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#oeikiyklay .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#oeikiyklay .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#oeikiyklay .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#oeikiyklay .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#oeikiyklay .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#oeikiyklay .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#oeikiyklay .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#oeikiyklay .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#oeikiyklay .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#oeikiyklay .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#oeikiyklay .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#oeikiyklay .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#oeikiyklay .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#oeikiyklay .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#oeikiyklay .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#oeikiyklay .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#oeikiyklay .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#oeikiyklay .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    lovo-cel gene therapy for Sickle Cell Disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.\r\n(ClinicalTrials. gov: NCT02140554;  Trial: HGB-206.)\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRomiplostim use in pregnant women with immune thrombocytopenia.\r\nSeven of 12 infants with neonatal thrombocytopenia had resolution of thrombocytopenia before discharge;  al 12 were discharged. Review of pregnancies in women exposed to romiplostim did not reveal any specific safety concerns for mothers, fetuses, or infants.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth.\r\nTargeting MIR17HG pre-RNA with clinically applicable antisense molecules disrupts the transcriptional and functional activities of lnc-17-92, causing potent anti-tumor effects both in vitro and in vivo in three pre-clinical animal models, including a clinically relevant PDX-NSG mouse model. This study establishes a novel oncogenic function of MIR17HG and provides potent inhibitors for translation to clinical trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAllogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity.\r\nSensitivity analyses removing patients with CVID and their matched transplanted patients confirm these results. AlloSCT prevents progressive morbidity associated with IEI in adults, which may outweigh the negative impact of TRM.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAn Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma.\r\nGrade =3 TEAEs included thrombocytopenia, anemia, lymphopenia, leukopenia, and neutropenia. Valemetostat demonstrated promising efficacy and tolerability in heavily pretreated patients, warranting further investigation in treating R/R ATL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBreakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey.\r\nDeath rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals. EPICOVIDEHA ( National Clinical Trials identifier NCT04733729) is an international open web-based registry for patients with HMs infected with SARS-CoV-2.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nEfficacy of JAK 1/2 inhibition in murine immune bone marrow failure.\r\nRUX only modestly suppressed lymphoid and erythroid hematopoiesis in normal and irradiated CByB6F1 mice. Our data supports clinical trials of JAK/STAT inhibitors in human AA and other immune bone marrow failure syndromes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.\r\nThe 2022 International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias makes extensive use of genomic data. This report aims to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with these hematologic neoplasms.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials.\r\nWe demonstrate the limited prognostic value of a single timepoint MRD evaluation, because MRD dynamics over time substantially impact PFS risk. These findings support MRD- status as a relevant endpoint during maintenance and confirm the increased progression risk in patients converting to MRD+ from MRD- status.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia.\r\nSafety profiles were consistent with those reported previously. Although they should be interpreted with caution, these exploratory findings suggest dabigatran could be an appropriate long-term anticoagulant for children with thrombophilia.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEnasidenib as Maintenance following Allogeneic Hematopoietic Cell Transplantation for IDH2-Mutated Myeloid Malignancies.\r\nThe study was registered at ClinicalTrials. gov (NCT03515512).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasms.\r\nMoreover, substantial BST elevations (e. g., >100 ng/mL) which would ordinarily prompt bone marrow biopsy, can result from TPSAB1 replications alone and thus be within 'normal' limits for certain individuals with HaT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants.\r\nOverall, our sequencing strategy proved powerful for producing high-quality ABO haplotypes and holds promise for generating similar collections for other blood groups. The publicly available collection of 154 haplotypes will serve as a valuable resource for molecular analyses of ABO, as well as studies about function and evolutionary history of ABO.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHealth-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.\r\nThis study is registered at clinicaltrials. gov as #NCT0357531.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHodgkin lymphoma and female fertility: a multicenter study in women treated with ABVD.\r\nThe number of pregnancies, births and the time to start a pregnancy in young women treated with ABVD for HL is not different to that of controls. Therefore, female with HL and treated by ABVD should be reassured in regards to fertility.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIncreasing tissue requirements in lymphoma trials may exclude patients with high risk disease or worse prognosis.\r\nThus, patients who undergo CNB have poor risk features, have inferior outcomes on frontline chemoimmunotherapy, are more likely to have inadequate tissue for molecular analyses and might not be able to meet tissue requirements of biomarker-driven clinical trials. Thus, increasing tissue requirements of biomarker driven clinical trials may result in exclusion of high risk DLBCL pts who need novel agents.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNovel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase.\r\nClass I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in bone marrow.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPatient perspectives on testing for clonal hematopoiesis of indeterminate potential.\r\nOur findings highlight the importance of effective risk communication and adequate psychosocial support when considering biomarkers of future risks in cancer survivors. This trial is registered at as NCT01468246.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProduction and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.\r\nThis report displays a complete system for the GMP-based production of iPSC-PLTs and the required non-clinical studies, and thus supports the iPLAT1 study, the first-in-human clinical trial of iPSC-PLTs, in a patient with allo-PTR and no compatible donor using the autologous product. It also serves as a comprehensive reference for the development of widely applicable allogeneic iPSC-PLTs and other cell products which use iPSC-derived progenitor cells as an MCB.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRNA-Regulatory Exosome Complex Suppresses an Apoptotic Program to Confer Erythroid Progenitor Cell Survival In Vivo.\r\nRNA-seq analysis of Exosc3-ablated BFU-E revealed elevated transcripts encoding multiple pro-apoptotic factors, and the mutant erythroid progenitors exhibited increased apoptosis. We propose that the EC controls an ensemble of apoptosis-regulatory RNAs, thereby promoting erythroid progenitor survival and developmental erythropoiesis in vivo.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe Prevalence of Thrombocytopenia in Patients with Acute Cancer-Associated Thrombosis.\r\nConcurrent diagnoses of CAT and thrombocytopenia are very common, especially among patients with hematologic malignancies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nU2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes.\r\nSomatic mutations encoding splicing factors may affect erythrocyte membrane components, biochemical properties, and RBC metabolic function, which underpin the development of atypical clones from erythroid precursors in MDS presenting with hemolysis. Future studies will explore the contribution of altered splicing to the development of acquired hemoglobinopathies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.\r\nThis data set suggests that a MSD donor remains the preferred choice in MDS over a haplo donor. Transplants with haploidentical donors result in satisfactory long-term outcome, justifying it's use when no better donor is available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nHaematologica\r\n    Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDonor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia.\r\nDetailed molecular analysis of B-ALL cells suggest that they are primed to undergo ferroptosis as they exhibit high steady-state oxidative stress potential, a low buffering capacity, and a disabled GPX4-independent secondary lipid peroxidation detoxification pathway. Finally, we validated the sensitivity of B-ALL to ferroptosis induction using patient-derived B-ALL samples.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHeterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients.\r\nIn conclusion, stratification of patients in the R-ISS stage II group can be improved by taking into account CA and ISS. However, this does not improve predictive performance of survival models.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOne disease, many faces.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPlasminogen activator-coated nanobubbles targeting cell-bound ÃŸ2-glycoprotein I as a novel thrombus-specific thrombolytic strategy.\r\nFinally, treatment of C3-gain-of-function mice with rtPA-tNBs, that target ÃŸ2-GPI deposited in kidney glomeruli, decreased fibrin deposition, and improved urinalysis data with a greater efficiency than untargeted NBs. Our findings suggest that targeting cell-bound ÃŸ2-GPI may represent an efficient and thrombus-specific thrombolytic strategy in both APS-related and APSunrelated thrombotic conditions.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReply to Shao and Zhou.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B cell impairment and increases the risk for infections - a retrospective matched cohort study.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSmall molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.\r\nSpecifically, SUMOi increased the number of memory B-cells as well as cytotoxic and memory T-cells, subsets that are attributed a key role within a coordinated antitumor immune response. In summary, our data constitute pharmacologic SUMOi as a powerful therapy in a subset of B-cell lymphomas causing massive remodeling of the normal B-cell and T-cell compartment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVon Willebrand factor in the plasma and in the tumor tissue predicts cancerassociated thrombosis and mortality.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome.\r\nA novel non-coding regulatory element was identified with a new computational approach using functionally validated primary AML LSC fractions and its role in LSC stemness validated through efficient CRISPR editing using methods optimized for OCI-AML22 LSC. Collectively, OCI-AML22 constitutes a valuable resource to uncover mechanisms governing CSC driven malignancies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCharacteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.\r\n4 out of 8 patients achieved morphologic leukemia-free state (MLFS) and minimal residual disease (MRD) negativity, 1 patient with MLFS and MRD positivity, 1 patient achieved complete remission with incomplete hematologic recovery (CRi) but MRD positivity, 1 patient with partial remission (PR), and 1 patient remained at stable disease (SD) status but had CLL1-positive AML blast clearance. These results suggested that anti-CLL1-based CAR-T cell immunotherapy can be considered as a well-tolerated and effective option for treating children with R/R-AML.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCompartment-specific mutational landscape of clonal hematopoiesis.\r\nPatients with overt myeloid malignancies showed higher mutation numbers and allele frequencies and a shifting mutation landscape, notably characterized by increasing prevalence of DNMT3A codon R882 variants. Collectively, our data provide novel insights into the genetics, evolution, and spatial and lineage-specific BM involvement of CH.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.\r\nThe impact of CCT on lymphocyte count is affected by use of bridging therapy but change in lymphocyte count is independently associated with efficacy. Studies aimed at investigating macrophage biology in this setting may suggest strategies to increase the efficacy of CCT and improve outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSplenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.\r\nGene expression analysis revealed enriched stemness and decreased myeloid lineage differentiation in spleen leukemic stem and progenitor cells (LSPCs). These results demonstrate that splenic RPM form a niche that maintains CML LSCs in a quiescent state, resulting in disease progression and resistance to therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Carotid Stenosis and Stroke: Medicines, Stents, Surgery - \"Wait-and-See\" or Protect?\r\nno abstract.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDual specificity tyrosine phosphorylation regulated kinase 1B inhibition promotes megakaryocyte polyploidization and platelet production.\r\nIn summary, DYRK1B plays an important role in megakaryocyte maturation and platelet production by interacting with cyclin D1 and P27. DYRK1B inhibition has potential therapeutic value in transient thrombocytopenia treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFactor XII explored with AlphaFold - opportunities for selective drug development.\r\nNot applicable.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHyperhomocysteinemia in cardiovascular diseases: revisiting observational studies and clinical trials.\r\nPatients with intermediate/major hyperhomocysteinemia should be properly assessed and treated for vitamin B deficiencies and inherited disorders according to current guidelines. Further trials are needed to assess the lowering homocysteine effect according to hyperhomocysteinemia categories at baseline.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInflammatory markers differentiate cerebral venous sinus thrombosis from mimics.\r\nIn conclusion, inflammatory markers in CVST were different from those in mimics. These markers, especially IL-6, could not only differentiate CVST from its mimics, but also evaluate CVST severity and prognosis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTEMPORARY REMOVAL: Direct oral anticoagulants in antithrombin deficiency: initial experience in a single center.\r\nIf you have any questions, please contact am-query@thieme. com.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUric Acid induces a pro-atherothrombotic phenotype in human endothelial cells by imbalancing TF/TFPI pathway.\r\nThe present in vitro study, shows that one of the mechanisms by which high levels of UA contributes to ED might be the imbalance between TF/TFPI levels in endothelial cells, shifting them to a non-physiological, pro-thrombotic phenotype. These UA effects might hypothetically explain, at least in part, the relationship observed between elevated plasma levels of UA and cardiovascular events.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#cpcwixcrht .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#cpcwixcrht .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#cpcwixcrht .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#cpcwixcrht .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#cpcwixcrht .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#cpcwixcrht .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#cpcwixcrht .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#cpcwixcrht .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#cpcwixcrht .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#cpcwixcrht .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#cpcwixcrht .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#cpcwixcrht .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#cpcwixcrht .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#cpcwixcrht .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#cpcwixcrht .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#cpcwixcrht .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#cpcwixcrht .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#cpcwixcrht .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#cpcwixcrht .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#cpcwixcrht .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#cpcwixcrht .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#cpcwixcrht .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#cpcwixcrht .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#cpcwixcrht .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#cpcwixcrht .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#cpcwixcrht .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#cpcwixcrht .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Ann Oncol\r\n    Somatic variation in normal tissues: friend or foe of cancer early detection?\r\nSomatic variation and the factors governing homeostasis of normal tissues should be taken into account when devising strategies for cancer prevention and early detection.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Do you need the immune system to cure ALL?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEndothelial cell-mediated venous thrombosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGVHD: pDCs providing VIP protection.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow thinly can one slice the AML diagnostic pie?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\niTPP: nature vs nurture?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLost in translation: cytoplasmic UBA1 and VEXAS syndrome.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredicting the future in MCL with MRD.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRaise the roof, build the floor.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCA Cancer J Clin\r\n    Prevention of device-related infections in patients with cancer: Current practice and future horizons.\r\nThe authors present many general principles for the prevention of these infections followed by specific device-related recommendations in a systematic manner. The continuous involvement and meaningful cooperation between regulatory entities, industry, specialty medical societies, hospitals, and infection control-targeted interventions, along with primary care and consulting health care providers, are al vital for the sustained reduction in the incidence of these preventable infections.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. \r\nHere, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to al patients with multiple myeloma.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCaregivers-an undervalued and underused essential. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFaecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. \r\nTherefore, faecal microbiota transplantation has been evaluated in patients with haematological malignancies for various indications, including Clostridioides difficile infection, eradication of multidrug-resistant bacteria, and steroid refractory acute GVHD. In addition, use of prophylactic faecal microbiota transplantation to restore the gut microbiota and improve patients' outcomes is being developed in the setting of allogeneic HCT, but also probably very soon in patients receiving autologous HCT or CAR T cells.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. \r\nThe role of third-generation TKIs as second-line therapy following front-line resistance to second-generation TKIs needs to be evaluated. New and mature data with TKI therapy in chronic myeloid leukaemia are producing observations that encourage continuous discussion of the optimal treatment recommendations and frameworks in chronic myeloid leukaemia.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Extracorporeal photopheresis in acute and chronic steroid-refractory graft-versus-host disease: an evolving treatment landscape.\r\nIn this \"Review\" article we would like to offer strategies for improving treatment results in patients with steroid-refractory GvHD by combining ruxolitinib with extracorporeal photopheresis (ECP), a leukapheresis-based immunomodulatory treatment frequently applied in T-cell mediated immune disease including GvHD. Our article explores key published evidence supporting the clinical efficacy of both ruxolitinib and ECP in the treatment of GvHD and highlights their potentially complementary mechanisms of action.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMiscellaneous\r\nmisc publications eg case reports, tools of the trade, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#dvpvrlkkqq .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#dvpvrlkkqq .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#dvpvrlkkqq .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#dvpvrlkkqq .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#dvpvrlkkqq .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#dvpvrlkkqq .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#dvpvrlkkqq .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#dvpvrlkkqq .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#dvpvrlkkqq .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#dvpvrlkkqq .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#dvpvrlkkqq .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#dvpvrlkkqq .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#dvpvrlkkqq .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#dvpvrlkkqq .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#dvpvrlkkqq .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#dvpvrlkkqq .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#dvpvrlkkqq .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#dvpvrlkkqq .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#dvpvrlkkqq .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#dvpvrlkkqq .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#dvpvrlkkqq .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#dvpvrlkkqq .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#dvpvrlkkqq .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#dvpvrlkkqq .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#dvpvrlkkqq .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#dvpvrlkkqq .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#dvpvrlkkqq .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Drug-Induced Hypersensitivity Syndrome and Eosinophils in Skin Biopsy in a patient with Pancytopenia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    An unusual myelofibrosis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCaulier A, Sankaran VG. Molecular and cellular mechanisms that regulate human erythropoiesis. Blood. 2022;139(16):2450-2459.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nElsaid R, Meunier S, Burlen-Defranoux O, etÂ al. A wave of bipotent T/ILC-restricted progenitors shapes the embryonic thymus microenvironment in a time-dependent manner. Blood. 2021;137(8):1024-1036.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFreeman SD, Valk P. Transplant in older adults with AML: genomic wheat and chaff. Blood. 2022;139(24):3459-3461.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFunk CR, Wang S, Chen KZ, etÂ al. PI3Kd/ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139(4):523-537.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMorphologic findings often provide guidance when immunophenotypic data overlap: a case of AML with cup-shaped nuclei.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSteiner L. Helping GATA1 make complex decisions. Blood. 2022;139(24):3457-3459.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTiming of allo-HCT in CMML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGermline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nInaccuracies in assignment of patient race and ethnicity: implications for unrelated donor searches and healthcare delivery.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeting FOLR1 in high-risk CBF2AT3-GLIS2 Pediatric AML with STRO-002 FOLR1-Antibody-Drug Conjugate.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    A survey on the patient perspective on cure in multiple myeloma. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMonika Asnani - addressing the unmet needs of sickle cell disease. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nShould patients with haemophilia receive gene therapy? \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe underrepresented majority. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVenetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLuspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOrgan dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#wjxlbfbxsc .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#wjxlbfbxsc .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#wjxlbfbxsc .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wjxlbfbxsc .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#wjxlbfbxsc .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#wjxlbfbxsc .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#wjxlbfbxsc .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#wjxlbfbxsc .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wjxlbfbxsc .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#wjxlbfbxsc .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#wjxlbfbxsc .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#wjxlbfbxsc .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#wjxlbfbxsc .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#wjxlbfbxsc .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wjxlbfbxsc .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#wjxlbfbxsc .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#wjxlbfbxsc .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wjxlbfbxsc .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#wjxlbfbxsc .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#wjxlbfbxsc .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#wjxlbfbxsc .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#wjxlbfbxsc .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#wjxlbfbxsc .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#wjxlbfbxsc .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#wjxlbfbxsc .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#wjxlbfbxsc .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#wjxlbfbxsc .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    \"Perioperative management of myeloproliferative neoplasms: a pan-Canadian physician survey and international expert opinion\".\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nA comment on: \"Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial\".\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nA reply to Moris et al.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nBlood Cancer J\r\n    Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nI-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nIntegrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    Blueprint for greater security of immunoglobulins for patients in Canada.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrioritising health equity alongside donation safety - Authors' reply.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPrioritising health equity alongside donation safety.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nShould unrelated haematopoietic progenitor cell donors be tested for CD36 in Japan?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    The WHO classification of haematolymphoid tumours: response to Swerdlow et al.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-09-30T15:42:29-04:00",
    "input_file": {}
  },
  {
    "path": "hema/09-23-2022/",
    "title": "Fri Sep 23 2022",
    "description": "86 articles - From Friday Sep 16 2022 to Friday Sep 23 2022",
    "author": [],
    "date": "2022-09-23",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nMiscellaneous\r\nLetters&Replies\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#rsyglwbmjo .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#rsyglwbmjo .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#rsyglwbmjo .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rsyglwbmjo .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#rsyglwbmjo .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#rsyglwbmjo .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#rsyglwbmjo .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#rsyglwbmjo .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rsyglwbmjo .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#rsyglwbmjo .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#rsyglwbmjo .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#rsyglwbmjo .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#rsyglwbmjo .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#rsyglwbmjo .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rsyglwbmjo .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#rsyglwbmjo .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#rsyglwbmjo .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rsyglwbmjo .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#rsyglwbmjo .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#rsyglwbmjo .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#rsyglwbmjo .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#rsyglwbmjo .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#rsyglwbmjo .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#rsyglwbmjo .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#rsyglwbmjo .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#rsyglwbmjo .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#rsyglwbmjo .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#lpsabmpfgw .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#lpsabmpfgw .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#lpsabmpfgw .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lpsabmpfgw .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#lpsabmpfgw .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#lpsabmpfgw .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#lpsabmpfgw .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#lpsabmpfgw .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lpsabmpfgw .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#lpsabmpfgw .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#lpsabmpfgw .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#lpsabmpfgw .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#lpsabmpfgw .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#lpsabmpfgw .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lpsabmpfgw .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#lpsabmpfgw .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#lpsabmpfgw .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lpsabmpfgw .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#lpsabmpfgw .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#lpsabmpfgw .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#lpsabmpfgw .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#lpsabmpfgw .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#lpsabmpfgw .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#lpsabmpfgw .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#lpsabmpfgw .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#lpsabmpfgw .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#lpsabmpfgw .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#miedfawaui .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#miedfawaui .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#miedfawaui .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#miedfawaui .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#miedfawaui .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#miedfawaui .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#miedfawaui .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#miedfawaui .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#miedfawaui .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#miedfawaui .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#miedfawaui .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#miedfawaui .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#miedfawaui .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#miedfawaui .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#miedfawaui .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#miedfawaui .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#miedfawaui .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#miedfawaui .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#miedfawaui .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#miedfawaui .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#miedfawaui .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#miedfawaui .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#miedfawaui .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#miedfawaui .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#miedfawaui .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#miedfawaui .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#miedfawaui .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients.\r\nFurthermore, patients harboring U2AF1 mutation might benefit from hypomethylating agents. This study demonstrated the critical role of VAF of mutations for risk stratification in MDS patients and may be incorporated in novel scoring systems.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImplications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia Across Therapy Subtypes.\r\nConversely, ts- AML and co-occurrence of mutations in TP53 were associated with poor median OS;  HR 2.3 (95% CI: 1.4-3.9;  p = 0.001) and HR 1.7 (95% CI: 0.9-3.1;  p = 0.06), respectively. The addition of venetoclax was associated with a non-significant improvement in CR/CRi and OS.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Analysis of rare disruptive germline mutations in 2,135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes. \r\nWhilst additional breast cancer susceptibility genes likely exist, those of high penetrance are likely to be of very low mutational frequency. Contention exists regarding the clinical utility of such genes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth.\r\nTargeting MIR17HG pre-RNA with clinically applicable antisense molecules disrupts the transcriptional and functional activities of lnc-17-92, causing potent anti-tumor effects both in vitro and in vivo in three pre-clinical animal models, including a clinically relevant PDX-NSG mouse model. This study establishes a novel oncogenic function of MIR17HG and provides potent inhibitors for translation to clinical trials.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBreakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey.\r\nDeath rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals. EPICOVIDEHA ( National Clinical Trials identifier NCT04733729) is an international open web-based registry for patients with HMs infected with SARS-CoV-2.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.\r\nDabrafenib plus trametinib demonstrated durable responses with a manageable safety profile consistent with previous observations in other indications and should be considered as a rituximab-free therapeutic option for patients with relapsed/refractory BRAF V600E mutation-positive HCL. This trial is registered at as #NCT02034110.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfficacy of JAK 1/2 inhibition in murine immune bone marrow failure.\r\nRUX only modestly suppressed lymphoid and erythroid hematopoiesis in normal and irradiated CByB6F1 mice. Our data supports clinical trials of JAK/STAT inhibitors in human AA and other immune bone marrow failure syndromes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.\r\nThe 2022 International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias makes extensive use of genomic data. This report aims to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with these hematologic neoplasms.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMalignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signalling in cutaneous T-cell lymphoma. \r\nTaken together, these findings indicate that malignant T cells secrete cytokines, which induce skin barrier defects through a JAK1/STAT3 dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for CTCL patients with advanced disease and a compromised skin barrier.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMissense mutations in PIEZO1, encoding the Piezo1 mechanosensor protein, define the Er red blood cell antigens. \r\nAnti-Er4 and anti-Er5 are implicated in severe hemolytic disease of the fetus and newborn (HDFN). Demonstration of Piezo1, present at just a few hundred copies on the surface of the red blood cell, as the site of a new blood group system highlights the potential antigenicity of even low abundance membrane proteins and contributes to our understanding of the in vivo characteristics of this important and widely studied protein in transfusion biology and beyond.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials.\r\nWe demonstrate the limited prognostic value of a single timepoint MRD evaluation, because MRD dynamics over time substantially impact PFS risk. These findings support MRD- status as a relevant endpoint during maintenance and confirm the increased progression risk in patients converting to MRD+ from MRD- status.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOutcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis. \r\nIn multivariate analysis, predictors of OS were high LDH at infusion, time to CAR-T failure PubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRecombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study.\r\nGrade 3/4 treatment-related adverse events (TRAEs) occurred in 86/167 (51%) patients;  TRAEs leading to discontinuation included pancreatitis (6%), allergic reactions (5%), increased alanine aminotransferase (1%), and hyperammonemia (1%). Study results demonstrate that IM JZP458 at 25/25/50 mg/m2 MWF is efficacious and has a safety profile consistent with those of other asparaginases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTracing the evolutionary history of blood cells to the unicellular ancestor of animals.\r\nWe finally showed that, in murine hematopoiesis, repression of CEBPa to maintain non-phagocytic lineages is commonly achieved by polycomb complex. These findings indicate that the initial blood cells emerged inheriting a unicellular organism program driven by CEBPa and that the program has been also seamlessly inherited in phagocytes of various animal species throughout evolution.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nvon Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A.\r\nRondoraptivon pegol is a first-in-class pro-hemostatic molecule that extended ~3-fold the half-life of substituted FVIII and increased ~2-fold endogenous FVIII levels in hemophilia patients. (NCT04677803).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    A transcriptome analysis of basal and stimulated VWF release from endothelial cells derived from type 1 VWD patients.\r\nWe have shown for the first time that transcriptome-wide differences exist between Type 1 VWD and control ECFCs. These differences may contribute to bleeding in Type 1 VWD, and further investigation may reveal novel biomarkers and therapeutic targets.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenome-wide CRISPR/Cas9 Screen Identifies Etoposide Response Modulators Associated with Outcomes in Pediatric AML.\r\nOur results confirmed the involvement of well-characterized genes, including TOP2A and ABCC1, as well as identified novel genes such as RAD54L2, PRKDC, and ZNF451 that have potential to be novel drug targets. This study demonstrates the ability for leveraging CRISPR/cas9 screening in conjunction with clinically relevant endpoints to make meaningful discoveries for the identification of prognostic biomarkers and novel therapeutic targets to overcome treatment resistance.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaplotype sequence collection of ABO blood group alleles by long-read sequencing reveals putative A1-diagnostic variants.\r\nOverall, our sequencing strategy proved powerful for producing high-quality ABO haplotypes and holds promise for generating similar collections for other blood groups. The publicly available collection of 154 haplotypes will serve as a valuable resource for molecular analyses of ABO, as well as studies about function and evolutionary history of ABO.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHodgkin lymphoma and female fertility: a multicenter study in women treated with ABVD.\r\nThe number of pregnancies, births and the time to start a pregnancy in young women treated with ABVD for HL is not different to that of controls. Therefore, female with HL and treated by ABVD should be reassured in regards to fertility.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLineage-switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.\r\nThe highest level of mutation occurred in naÃ¯ve CD4+ T cells (median 51.2%;  range 3.8-93.5%). This study reveals an unexpected lineage-switch of BRAFV600E mutation in high risk LCH, which may influence monitoring strategies for the potential withdrawal of inhibitor treatment and has new implications for the pathogenesis of neurodegeneration, which occurred in 4 patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNovel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase.\r\nClass I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in bone marrow.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPatient perspectives on testing for clonal hematopoiesis of indeterminate potential.\r\nOur findings highlight the importance of effective risk communication and adequate psychosocial support when considering biomarkers of future risks in cancer survivors. This trial is registered at as NCT01468246.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromboembolic events, bleeding, and mortality in patients with cerebral venous thrombosis: a nationwide cohort study.\r\nRisks were not elevated for myocardial infarction. Clinicians should be aware of the importance of age and sex heterogeneity in the prognosis of CVT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTracking the Progeny of Virus-specific T-cell Products in Patients Post-Transplant using TCR-Sequencing.\r\nAdditionally, we demonstrated persistence of virus-specific T cells derived from the T-cell products in most patients who did not show viral reactivations. This study demonstrates that virus-specific T cells from prophylactically infused multi-antigen-specific T-cell products can expand in response to antigen encounter in vivo and even persist in the absence of early viral reactivations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nU2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes.\r\nSomatic mutations encoding splicing factors may affect erythrocyte membrane components, biochemical properties, and RBC metabolic function, which underpin the development of atypical clones from erythroid precursors in MDS presenting with hemolysis. Future studies will explore the contribution of altered splicing to the development of acquired hemoglobinopathies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution.\r\nIn the relapsed setting, a significant survival benefit was observed beyond the year 2000, but still with significant differences among patients without Ps, PPs and EMPs (37 vs 22 vs 16months, p=0.003). Importantly, rescue therapy with combinations of proteasome-inhibitors plus immunomodulatory drugs was associated with prolonged OS from first relapse (over 6years), even in patients with EMPs.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nHaematologica\r\n    Clinical impact of clonal hematopoiesis on severe COVID-19 patients without canonical risk factors.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nContribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDonor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGenome-wide CRISPR screens identify ferroptosis as a novel therapeutic vulnerability in acute lymphoblastic leukemia.\r\nDetailed molecular analysis of B-ALL cells suggest that they are primed to undergo ferroptosis as they exhibit high steady-state oxidative stress potential, a low buffering capacity, and a disabled GPX4-independent secondary lipid peroxidation detoxification pathway. Finally, we validated the sensitivity of B-ALL to ferroptosis induction using patient-derived B-ALL samples.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMitigation of gastrointestinal graft versus host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B cell impairment and increases the risk for infections - a retrospective matched cohort study.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSmall molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.\r\nSpecifically, SUMOi increased the number of memory B-cells as well as cytotoxic and memory T-cells, subsets that are attributed a key role within a coordinated antitumor immune response. In summary, our data constitute pharmacologic SUMOi as a powerful therapy in a subset of B-cell lymphomas causing massive remodeling of the normal B-cell and T-cell compartment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nVon Willebrand factor in the plasma and in the tumor tissue predicts cancerassociated thrombosis and mortality.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells.\r\nThese data highlight the potential of elraglusib as an immune-modulatory agent and demonstrate the benefit of a sequential approach with immune checkpoint inhibition followed by GSK-3ÃŸ inhibition in melanoma and provide a rationale for clinical investigation of elraglusib combined with immune checkpoint inhibitory molecules, including those targeting PD-1, TIGIT and LAG-3. This has several potential implications for current immunotherapy regimes, including possibly reducing the intensity of anti-PD-1 mAb treatment needed for response in patients receiving elraglusib, especially given the benign adverse event profile of elraglusib observed to date. Based on these data, a clinical study of elraglusib, an anti-PD-1 mAb and chemotherapy is ongoing (NCT NCT05239182).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLancet Haematol\r\n    Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study.\r\nOur data suggest that HPA-matched transfusions lead to a larger median platelet count increment than HPA-unmatched transfusions, but whether HPA matching is also associated with a reduced risk of bleeding remains unknown. Funding Sanquin.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome.\r\nA novel non-coding regulatory element was identified with a new computational approach using functionally validated primary AML LSC fractions and its role in LSC stemness validated through efficient CRISPR editing using methods optimized for OCI-AML22 LSC. Collectively, OCI-AML22 constitutes a valuable resource to uncover mechanisms governing CSC driven malignancies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCompartment-specific mutational landscape of clonal hematopoiesis.\r\nPatients with overt myeloid malignancies showed higher mutation numbers and allele frequencies and a shifting mutation landscape, notably characterized by increasing prevalence of DNMT3A codon R882 variants. Collectively, our data provide novel insights into the genetics, evolution, and spatial and lineage-specific BM involvement of CH.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nImpact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.\r\nThe impact of CCT on lymphocyte count is affected by use of bridging therapy but change in lymphocyte count is independently associated with efficacy. Studies aimed at investigating macrophage biology in this setting may suggest strategies to increase the efficacy of CCT and improve outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Dual specificity tyrosine phosphorylation regulated kinase 1B inhibition promotes megakaryocyte polyploidization and platelet production.\r\nIn summary, DYRK1B plays an important role in megakaryocyte maturation and platelet production by interacting with cyclin D1 and P27. DYRK1B inhibition has potential therapeutic value in transient thrombocytopenia treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUric Acid induces a pro-atherothrombotic phenotype in human endothelial cells by imbalancing TF/TFPI pathway.\r\nThe present in vitro study, shows that one of the mechanisms by which high levels of UA contributes to ED might be the imbalance between TF/TFPI levels in endothelial cells, shifting them to a non-physiological, pro-thrombotic phenotype. These UA effects might hypothetically explain, at least in part, the relationship observed between elevated plasma levels of UA and cardiovascular events.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#qkmihvglmj .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#qkmihvglmj .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#qkmihvglmj .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qkmihvglmj .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#qkmihvglmj .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#qkmihvglmj .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#qkmihvglmj .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#qkmihvglmj .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qkmihvglmj .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qkmihvglmj .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#qkmihvglmj .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#qkmihvglmj .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qkmihvglmj .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#qkmihvglmj .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qkmihvglmj .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qkmihvglmj .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#qkmihvglmj .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qkmihvglmj .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qkmihvglmj .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qkmihvglmj .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#qkmihvglmj .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#qkmihvglmj .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#qkmihvglmj .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#qkmihvglmj .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#qkmihvglmj .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#qkmihvglmj .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#qkmihvglmj .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Approach to a patient with \"double refractory\" chronic lymphocytic leukemia: \"Double, double toil and trouble\" (Shakespeare). \r\nWe further examine the mechanism of resistance to these targeted agents and discuss the current landscape for managing this patient population. Finally, we explore data supporting promising new agents, including non-covalent BTKi, chimeric antigen receptor T cells, and additional classes of agents currently in development.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nManagement of front line chronic lymphocytic leukemia. \r\nAlthough these agents have usually manageable side effects, toxicities might limit choices for the individual patient. We here discuss latest trial data and propose a treatment algorithm for frontline treatment of CLL according to fitness and relevant genetic risk factors like IGHV mutational status and TP53 aberrations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nManagement of relapsed/refractory Chronic Lymphocytic Leukemia. \r\nWe will also discuss important considerations when sequencing these available treatments. The recent advances in this disease are significant steps forward, and raise new questions of how these available drugs should be given as well as how we can continue to improve the treatment of CLL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    The prognostic value of TILs in stage III colon cancer must consider sidedness. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    AML relapse after a TIGIT race.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDiffuse myocardial fibrosis as an SCD biomarker.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGVHD: pDCs providing VIP protection.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHow thinly can one slice the AML diagnostic pie?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\niTPP: nature vs nurture?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMutant CALR's \"sweet tooth\".\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPredicting the future in MCL with MRD.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTet2 helps blood cells balance in air.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTranexamic acid as a stopgap for low platelets?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets.\r\ng., 3,10-dibromofascaplysin combined with olaparib) to exhibit therapeutic potential against various cancers by regulating RCD subroutines. In short, the information provided in this review on the regulation of cell death by indole alkaloids against different targets is expected to be beneficial for the design of novel molecules with greater targeting and biological properties, thereby facilitating the development of new strategies for cancer therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nTGF-ÃŸ signaling in the tumor metabolic microenvironment and targeted therapies.\r\nThen, we review the metabolic reprogramming in the TMME and elaborate on the contribution of TGF-ÃŸ to metabolic rewiring at the cellular (intracellular), tissular (intercellular), and organismal (cancer-host) levels. Furthermore, we propose three potential applications of targeting TGF-ÃŸ-dependent mechanism reprogramming, paving the way for TGF-ÃŸ-related antitumor therapy from the perspective of metabolism.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nLeukemia\r\n    All that glitters is not LGL Leukemia.\r\nHowever, from a clinical perspective, the relationships between T-LGLL and other borderline and overlapping conditions, including reactive cell expansions, clonal hematopoiesis of indeterminate potential (CHIP) and unrelated clonopathies are not fully established, sometimes making the diagnosis of T cell malignancy challenging. In this review specifically focused on the topic of clonality of T-LGL disorders we will discuss the rationale of the appropriate steps to aid in distinguishing LGLL from its mimics, also attempting to provide new clues to stimulate further investigations designed to move this field forward.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMiscellaneous\r\nmisc publications eg case reports, tools of the trade, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#eaogmjqljc .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#eaogmjqljc .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#eaogmjqljc .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#eaogmjqljc .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#eaogmjqljc .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#eaogmjqljc .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#eaogmjqljc .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#eaogmjqljc .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#eaogmjqljc .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#eaogmjqljc .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#eaogmjqljc .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#eaogmjqljc .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#eaogmjqljc .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#eaogmjqljc .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#eaogmjqljc .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#eaogmjqljc .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#eaogmjqljc .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#eaogmjqljc .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#eaogmjqljc .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#eaogmjqljc .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#eaogmjqljc .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#eaogmjqljc .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#eaogmjqljc .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#eaogmjqljc .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#eaogmjqljc .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#eaogmjqljc .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#eaogmjqljc .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Neutrophilic Eccrine Hidradenitis in a pediatric patient with Acute Myeloid Leukemia.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Berzuini A, Bianco C, Paccapelo C, etÂ al. Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood. 2020;136(6):766-768.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCannabidiol attenuates hyperalgesia in a mouse model of sickle cell disease. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCaulier A, Sankaran VG. Molecular and cellular mechanisms that regulate human erythropoiesis. Blood. 2022;139(16):2450-2459.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDuault C, Kumar A, Taghi Khani A, etÂ al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021;138(16):1465-1480.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nElsaid R, Meunier S, Burlen-Defranoux O, etÂ al. A wave of bipotent T/ILC-restricted progenitors shapes the embryonic thymus microenvironment in a time-dependent manner. Blood. 2021;137(8):1024-1036.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFunk CR, Wang S, Chen KZ, etÂ al. PI3Kd/ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139(4):523-537.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGelatinous transformation of bone marrow and concomitant fungal infection in a patient with HIV.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntroduction to the How I Treat Series on \"How I Manage High-Risk Patients Following Allogeneic Transplant\".\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\niPLAT1: The first-in-human clinical trial of iPSC-derived platelets as a phase 1 autologous transfusion study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLong-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMorphologic findings often provide guidance when immunophenotypic data overlap: a case of AML with cup-shaped nuclei.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSadler B, Christopherson PA, Haller G, Montgomery RR, Di Paola J; Zimmerman Program Investigators. von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene. Blood. 2021;137(23):3277-3283.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSingle Cell Genomics - a new chapter in how technological advances propel Hemato-Oncology.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTiming of allo-HCT in CMML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTumburu L, Ghosh-Choudhary S, Seifuddin FT, etÂ al. Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease. Blood. 2021;137(22):3116-3126.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIxazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    A Trp11Arg Substitution in the ÃŸ3 Signal Peptide Prevents Expression of aIIbÃŸ3 in Patients with Glanzmann Thrombasthenia. \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#vimifnobeg .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#vimifnobeg .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#vimifnobeg .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vimifnobeg .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#vimifnobeg .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#vimifnobeg .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#vimifnobeg .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#vimifnobeg .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vimifnobeg .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#vimifnobeg .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#vimifnobeg .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#vimifnobeg .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#vimifnobeg .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#vimifnobeg .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vimifnobeg .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#vimifnobeg .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#vimifnobeg .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vimifnobeg .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#vimifnobeg .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#vimifnobeg .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#vimifnobeg .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#vimifnobeg .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#vimifnobeg .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#vimifnobeg .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#vimifnobeg .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#vimifnobeg .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#vimifnobeg .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    A reply to Moris et al.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDeterminants of early triage for hospitalization in MPN patients with COVID-19.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIncreased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSecondary-type mutations do not impact prognosis in AML with mutated NPM1.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM). \r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nReply to the Letter to the Editor \"Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification\" by Hannoun-Levi et al.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nT Cell Receptor Sequencing Reveals Reduced Clonal Breadth of T Cell Responses against SARS-CoV-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-09-24T01:43:03-04:00",
    "input_file": {}
  },
  {
    "path": "hema/09-16-2022/",
    "title": "Fri Sep 16 2022",
    "description": "97 articles - From Friday Sep 09 2022 to Friday Sep 16 2022",
    "author": [],
    "date": "2022-09-16",
    "categories": [],
    "contents": "\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nparm_toc.knith1 {font-size: 34px;}\r\n       h1.title {font-size: 38px;}\r\n       h2 {font-size: 30px;}\r\n       h3 {font-size: 24px;}\r\n       h4 {font-size: 18px;}\r\n       h5 {font-size: 16px;}\r\n       h6 {font-size: 12px;}\r\n       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}\r\n       pre:not([class]) { background-color: white }\r\n  code{white-space: pre-wrap;}\r\n  span.smallcaps{font-variant: small-caps;}\r\n  span.underline{text-decoration: underline;}\r\n  div.column{display: inline-block; vertical-align: top; width: 50%;}\r\n  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\r\n  ul.task-list{list-style: none;}\r\n    code{white-space: pre;}\r\nif (window.hljs) {\r\n  hljs.configure({languages: []});\r\n  hljs.initHighlightingOnLoad();\r\n  if (document.readyState && document.readyState === \"complete\") {\r\n    window.setTimeout(function() { hljs.initHighlighting(); }, 0);\r\n  }\r\n}\r\n\r\n.main-container {\r\n  max-width: 940px;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n}\r\nimg {\r\n  max-width:100%;\r\n}\r\n.tabbed-pane {\r\n  padding-top: 12px;\r\n}\r\n.html-widget {\r\n  margin-bottom: 20px;\r\n}\r\nbutton.code-folding-btn:focus {\r\n  outline: none;\r\n}\r\nsummary {\r\n  display: list-item;\r\n}\r\npre code {\r\n  padding: 0;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs {\r\n  display: inline-table;\r\n  max-height: 500px;\r\n  min-height: 44px;\r\n  overflow-y: auto;\r\n  border: 1px solid #ddd;\r\n  border-radius: 4px;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {\r\n  content: \"<U+E258>\";\r\n  border: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open:before {\r\n  content: \"<U+E259>\";\r\n  font-family: 'Glyphicons Halflings';\r\n  display: inline-block;\r\n  padding: 10px;\r\n  border-right: 1px solid #ddd;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li.active {\r\n  display: block;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li > a,\r\n.tabset-dropdown > .nav-tabs > li > a:focus,\r\n.tabset-dropdown > .nav-tabs > li > a:hover {\r\n  border: none;\r\n  display: inline-block;\r\n  border-radius: 4px;\r\n  background-color: transparent;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs.nav-tabs-open > li {\r\n  display: block;\r\n  float: none;\r\n}\r\n\r\n.tabset-dropdown > .nav-tabs > li {\r\n  display: none;\r\n}\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\nGuidelines\r\nMeta-analysis\r\nOriginal articles\r\nReviews&Editorials\r\nMiscellaneous\r\nLetters&Replies\r\n\r\n\r\n\r\n$(function () {\r\n          $('#goTop').goTop({\"container\":\"\",\"appear\":200,\"scrolltime\":800,\"src\":\"fas fa-chevron-up\",\"width\":45,\"place\":\"left\",\"color\":\"\",\"fadein\":500,\"fadeout\":500,\"opacity\":0.5,\"marginX\":2,\"marginY\":2,\"zIndex\":9});\r\n         });\r\nGuidelines\r\nGuidelines, position statements, white papers, technical reviews, consensus statements, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#unxpybspjt .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#unxpybspjt .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#unxpybspjt .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#unxpybspjt .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#unxpybspjt .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#unxpybspjt .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#unxpybspjt .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#unxpybspjt .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#unxpybspjt .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#unxpybspjt .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#unxpybspjt .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#unxpybspjt .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#unxpybspjt .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#unxpybspjt .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#unxpybspjt .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#unxpybspjt .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#unxpybspjt .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#unxpybspjt .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#unxpybspjt .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#unxpybspjt .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#unxpybspjt .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#unxpybspjt .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#unxpybspjt .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#unxpybspjt .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#unxpybspjt .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#unxpybspjt .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#unxpybspjt .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nMeta-analysis\r\nmeta-analyses and systematic reviews\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#hotmevzmaa .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#hotmevzmaa .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#hotmevzmaa .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#hotmevzmaa .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#hotmevzmaa .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#hotmevzmaa .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#hotmevzmaa .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#hotmevzmaa .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#hotmevzmaa .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#hotmevzmaa .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#hotmevzmaa .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#hotmevzmaa .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#hotmevzmaa .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#hotmevzmaa .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#hotmevzmaa .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#hotmevzmaa .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#hotmevzmaa .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#hotmevzmaa .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#hotmevzmaa .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#hotmevzmaa .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#hotmevzmaa .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#hotmevzmaa .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#hotmevzmaa .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#hotmevzmaa .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#hotmevzmaa .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#hotmevzmaa .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#hotmevzmaa .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    \r\n\r\n\r\nOriginal articles\r\nRCT, clinical trials, retrospective studies, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#qdgrierdwh .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#qdgrierdwh .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#qdgrierdwh .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qdgrierdwh .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#qdgrierdwh .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#qdgrierdwh .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#qdgrierdwh .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#qdgrierdwh .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qdgrierdwh .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#qdgrierdwh .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#qdgrierdwh .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#qdgrierdwh .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#qdgrierdwh .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#qdgrierdwh .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qdgrierdwh .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#qdgrierdwh .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#qdgrierdwh .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qdgrierdwh .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#qdgrierdwh .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#qdgrierdwh .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#qdgrierdwh .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#qdgrierdwh .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#qdgrierdwh .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#qdgrierdwh .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#qdgrierdwh .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#qdgrierdwh .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#qdgrierdwh .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis.\r\nAdV disease after HCT remains a challenge. Better antiviral modalities are necessary.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma.\r\nIn terms of specific gene mutations, adverse OS was mostly associated with PPM1D mutations (hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.13-2.67, P=0.011). In summary, we found that CH is associated with an increased risk of non-lymphoma-related death after ASCT, which suggests that lymphoma survivors with CH may need intensified surveillance strategies to prevent and treat late complications.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDifferential Prognostic Impact of RUNX1 Mutations According to Frontline Therapy in Patients with Acute Myeloid Leukemia.\r\nA multivariate analysis showed possible interaction between RUNX1 mutation status and treatment, suggesting a differential prognostic impact of RUNX1 mutations when patients received IC versus LIT with VEN. In summary, the prognostic impact of mRUNX1 AML may be treatment-dependent, and the presence of RUNX1 mutations may not impact clinical outcomes when venetoclax-based regimens are used.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nErythroferrone contributes to iron mobilization for embryo erythropoiesis in iron-deficient mouse pregnancies.\r\nThe effect was exacerbated under iron-deficient conditions where ERFE KO embryos had higher hepcidin, lower Hb and Hct, and lower brain iron concentration compared to WT embryos, indicative of iron restriction. Thus, under iron-deficient conditions, maternal and embryo ERFE facilitate iron mobilization for embryonic erythropoiesis.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTime-dependent prediction of mortality and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation using machine learning.\r\nThese gradient boosting machine models provide well-calibrated, time-dependent risk predictions and achieved areas under the receiver-operating characteristic of 0.92 and 0.83 and areas under the precision-recall curve of 0.58 and 0.62 for prediction of mortality and CMV reactivation, respectively, in a 21-day time window. Both models were successfully validated in a prospective, non-interventional study and performed on par with expert hematologists in a pilot comparison.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTransferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent ÃŸ-thalassemia.\r\nRemarkably, BM Tfr2 deletion is also sufficient to avoid long-term blood transfusions required for survival of Hbb th1/th2 animals, preventing mortality due to chronic anemia and reducing transfusion-associated complications, such as progressive iron-loading. Altogether, TFR2 targeting might represent a promising therapeutic option also for TDT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnderstanding pulse oximetry in hematology patients: Hemoglobinopathies, racial differences and beyond.\r\nIn addition, a range of challenges may arise in patients with increased levels of methemoglobin - whether acquired or inherited - carboxyhemoglobin, or in patients with a subset of inherited variant hemoglobins. It is important for Hematologists, and indeed al clinicians who rely on pulse oximetry, to understand the principles and limitations of this ubiquitous test.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.\r\nAPOBEC mutational signatures are frequent in RTK-driven LUADs and increase under the selective pressure of osimertinib in EGFR-mutant lung cancer. APOBEC mutational signature enrichment in subclonal mutations, private mutations acquired after osimertinib treatment, and areas of large scale genomic rearrangements highlights a potentially fundamental role for APOBEC mutagenesis in the development of resistance to targeted therapies, which may be potentially exploited to overcome such resistance.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer.\r\nThese findings from the largest and most comprehensive study to date of cfDNA from patients with advanced BTC highlight the utility of cfDNA analysis in current management of this disease. Characterization of oncogenic drivers and mechanisms of therapeutic resistance in this study will inform drug development efforts to reduce mortality for patients with BTC.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.\r\nDabrafenib plus trametinib demonstrated durable responses with a manageable safety profile consistent with previous observations in other indications and should be considered as a rituximab-free therapeutic option for patients with relapsed/refractory BRAF V600E mutation-positive HCL. This trial is registered at as #NCT02034110.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDetecting measurable residual disease beyond 10-4 through an IGHV leader-based NGS approach improves prognostic stratification in CLL.\r\nPFS of patients in this MRD range was significantly shorter, compared to patients with MRD <10-5 (HR 4.0, [95%CI 1.6-10.3], P=0.004), but significantly longer, compared to patients with MRD =10-4 (HR 0.44, [95%CI 0.23-0.87], P=0.018). These results support the clinical utility of the IGHV leader-based NGS assay.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEffective treatment of low risk acute GVHD with itacitinib monotherapy.\r\nThere were no significant differences between groups at 1-year for non-relapse mortality (4% vs 11%, p=0.21), relapse (18% vs 21%, p=0.64), chronic GVHD (28% vs 33%, p=0.33) or survival (88% vs 80%, p=0.11). Itacitinib monotherapy seems to be a safe and effective alternative to SCS treatment for LR GVHD that deserves further investigation.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEfficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents.\r\nSeven (35%) patients died (3 of progressive disease, 4 of adverse events [1 treatment-related, 3 unrelated]). Cilta-cel induced favorable responses in patients with relapsed/refractory MM and prior exposure to anti-BCMA treatment who have exhausted other therapies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEVI1 drives leukemogenesis through aberrant ERG activation.\r\nSuppression of ERG induces terminal differentiation of EVI1-driven AML cells, whereas ectopic expression of ERG abrogates their dependence on EVI1, indicating that major oncogenic functions of EVI1 are mediated through aberrant transcriptional activation of ERG. Interfering with this regulatory axis may provide entry points for the development of rational targeted therapies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMacrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo.\r\nFinally, we show that genetic disruption of IRAK4 does not result in negative selection of human CLL cell lines xenografted in immunodeficient mice. The obtained data suggest that TLR-signals are unlikely to represent a major driver of CLL/RS cell proliferation and provide further evidence that signals from macrophages and the BCR promote the growth and survival of CLL and RS cells in vivo.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRecombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study.\r\nGrade 3/4 treatment-related adverse events (TRAEs) occurred in 86/167 (51%) patients;  TRAEs leading to discontinuation included pancreatitis (6%), allergic reactions (5%), increased alanine aminotransferase (1%), and hyperammonemia (1%). Study results demonstrate that IM JZP458 at 25/25/50 mg/m2 MWF is efficacious and has a safety profile consistent with those of other asparaginases.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTd LGL LEUKEMIA IDENTIFIES A SUBSET WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF AN INTERNATIONAL COHORT OF 137 PATIENTS.\r\nOverall, Tgd patients displayed reduced survival with respect to Tab patients (p=0.0017). Although there was no difference in STAT3 mutation frequency, our results showed that Tgd LGLL represents a subset of T-LGLL characterized by more frequent symptoms and reduced survival as compared to Tab LGLL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe end of the beginning: Application of single cell sequencing to chronic lymphocytic leukemia (CLL).\r\nHerein, we review the recent forays into the application of single cell analysis to CLL, which are already revealing new understanding of the natural progression of CLL, the impact of novel therapies, and the interactions with co-evolving non-malignant immune cell populations. As we emerge from the 'end of the beginning' of this technologic revolution, CLL stands poised to reap the benefits of single cell analysis from the standpoints of uncovering fresh fundamental biology, and of providing a path to devising regimes of personalized diagnosis, treatment, and monitoring.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTrafficking between clonally related peripheral T helper cells and tissue-resident T helper cells in chronic GVHD.\r\nDeficiency of IL-21R, BCL6, or T-bet in donor T cells markedly reduced the proportions of Tph cells in the blood and Trh cells in GVHD target tissues and reduced T-B interaction in the lymphoid aggregates. These results indicate that clonally related pathogenic Tph cells and Trh cells traffic between the blood and chronic GVHD target tissues, and that IL-21R-BCL6 signaling and T-bet are required for the development and expansion of Tph and Trh cells in the pathogenesis of cGVHD.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nvon Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A.\r\nRondoraptivon pegol is a first-in-class pro-hemostatic molecule that extended ~3-fold the half-life of substituted FVIII and increased ~2-fold endogenous FVIII levels in hemophilia patients. (NCT04677803).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.\r\nIn conclusion, belumosudil treatment was associated with lung-specific clinical responses for subjects with BOS, which were more commonly observed in less advanced disease. Optimization of treatment response evaluations remains a challenge in patients with BOS.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.\r\nThus, the correlation of BRAFV600E with inferior clinical outcome is (primarily) driven by its association with disease extents known for high rates of progression or relapse, including multisystem LCH. These findings advance our understanding of factors underlying the remarkable clinical heterogeneity of LCH, but also question the independent prognostic value of lesional BRAFV600E status.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nEltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, Middle East, and Turkey: final analysis of CITE.\r\nAdverse events occurred in 50.9% of patients (n=116), the most common being upper respiratory tract infection (8.3%) and headache (6.6%). These findings confirmed effectiveness of eltrombopag treatment in routine practice and reassured that real-world compliance to eltrombopag prescribed doses and dietary instructions in the Asia-Pacific, Middle East, and Turkey were in line with current recommendations.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry.\r\nIn multivariate analysis (S/A/R mutations excluded due to low event rates), a diagnosis of MCL-AHN (HR 4.7, 95% CI 1.7 - 13.0, p = 0.001) and abnormal karyotype (HR 5.6, 95% CI 1.4 - 13.3, p = 0.02) were associated with inferior OS;  KIT D816V positivity (HR 0.33, 95% CI 0.11 - 0.98, p = 0.04) and midostaurin treatment (HR 0.32, 95% CI 0.08 - 0.72, p = 0.008) were associated with superior OS. These data provide the most comprehensive snapshot of the clinicopathologic, molecular, and treatment landscape of MCL to date, and should help further inform subtyping and prognostication of MCL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNADPH oxidase 2 limits amplification of IL-1ÃŸ-G-CSF axis and an immature neutrophil subset in murine lung inflammation.\r\nThus, neutrophil-produced IL-1ÃŸ and downstream G-CSF act sequentially but non-redundantly with LTB4 to deploy neutrophils and amplify inflammation in CGD mice following inhalation of zymosan. NOX2 plays a critical role in dampening multiple components of a feed-forward pipeline for neutrophil recruitment, and these findings highlight NOX2 as a key regulator of neutrophil number, subsets and function at inflamed sites.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPeri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.\r\nAlloHCT for select patients at any time following CAR-T failure (n=16) led to durable responses in over half at one-year. These data provide a benchmark for future clinical trials in patients with progression post-CAR-T, an unmet clinical need.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels.\r\nMoreover, RNA sequencing of blood-resident EÂµ-myclymphoma cells from TpoTgand wild-type mice after tumour transplant revealed upregulation of hallmark gene sets associated with inflammatory response in TpoTg mice. We propose that a pro-inflammatory microenvironment in TpoTgmice promoted lymphoma progression.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProspective hemophilia inhibitor PUP study reveals distinct antibody signatures during FVIII inhibitor eradication.\r\nInterestingly, one patient with partial ITI success and one patient with ITI failure developed apparent oligoreactive FVIII-binding antibodies during ITI. The explanation of the true nature of these antibodies requires more comprehensive follow-ups in future studies.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSequential Pembrolizumab and AVD is Highly Effective at any PD-L1 Expression Level in Untreated Hodgkin Lymphoma.\r\nThe high response rates observed at al PD-ligand levels suggest that even low levels of PD ligand expression are sufficient for response to PD-1 blockade in untreated cHL. An international phase II trial (NCT05008224) to confirm these findings is ongoing.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children.\r\nIn available pre-HCT samples, there were no differences in complement biomarkers in those with SCD and those without, though SCD patients did have significantly higher markers of endothelial activation, sVCAM-1 and p-selectin levels. In conclusion, children with SCD merit careful screening for TA-TMA post HCT, particularly those receiving a haploidentical HCT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe outcome of older adults with classic Hodgkin lymphoma in British Columbia.\r\nWith a median follow-up of 9 years, 5-year disease specific (DSS) and overall survival (OS) have improved by decade comparison (both p 70 even in the mod-ern treatment era. Further, treatment-related toxicity remains a significant concern and use of bleo-mycin should be avoided in most patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.\r\nThe crude prevalence of LC-MGUS in CKD patients was 0.5%. We conclude that current reference intervals for FLC and FLC ratio are inaccurate in CKD patients and propose new eGFR based reference intervals to be implemented.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaematologica\r\n    Activation of lncRNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins.\r\nOverall, we provided novel important insights into NEAT1 role in supporting MM cells adaptation to stressful conditions by improving the maintenance of DNA integrity. Taken together, our results suggest that NEAT1, and probably PS organelles, could represent a potential therapeutic target for MM treatment.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAdverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nClinical impact of clonal hematopoiesis on severe COVID-19 patients without canonical risk factors.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMitigation of gastrointestinal graft versus host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nResponse-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTargeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in Tcell acute lymphoblastic leukemia.\r\nTAL1-positive, AKT-activated T-ALL cells were very sensitive to PIK-75, as evidenced by the growth inhibition and apoptosis induction, while T-ALL cells that exhibited activation of the JAK-STAT pathway were insensitive to this drug. Together, our study demonstrates a strategy targeting two types of core machineries mediated by oncogenic transcription factors and signaling pathways in T-ALL.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTreatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population.\r\nNot available.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells.\r\nThese data highlight the potential of elraglusib as an immune-modulatory agent and demonstrate the benefit of a sequential approach with immune checkpoint inhibition followed by GSK-3ÃŸ inhibition in melanoma and provide a rationale for clinical investigation of elraglusib combined with immune checkpoint inhibitory molecules, including those targeting PD-1, TIGIT and LAG-3. This has several potential implications for current immunotherapy regimes, including possibly reducing the intensity of anti-PD-1 mAb treatment needed for response in patients receiving elraglusib, especially given the benign adverse event profile of elraglusib observed to date. Based on these data, a clinical study of elraglusib, an anti-PD-1 mAb and chemotherapy is ongoing (NCT NCT05239182).\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study.\r\nOur data suggest that HPA-matched transfusions lead to a larger median platelet count increment than HPA-unmatched transfusions, but whether HPA matching is also associated with a reduced risk of bleeding remains unknown. Funding Sanquin.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.\r\nInterpretation These data suggest that tisagenlecleucel has antitumour activity and has an acceptable safety profile for young children and infants with B-cell precursor acute lymphoblastic leukaemia. Funding None.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.\r\nThis analysis confirms and quantifies the increased risk of SMN in children with ALL after conditioning with TBI. Future strategies to avoid TBI will need careful tailoring within prospective, controlled studies to prevent unfavorable outcomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nPregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden.\r\nIncidence was 12.2 per 100.000 pregnancies. In summary, preterm birth was an important complication in MPN pregnancies, while maternal complications were less common than previously reported.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProspective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.\r\nSequential analysis of variant allelic frequency of mutations like SRSF2 did not reveal an impact of ROM on clonal evolution in both responders and non-responders. In summary, our study confirms the safety and efficacy of ROM in LR-MDS patients and may allow to better define subgroups of patients with a high likelihood of response.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThromb Haemost\r\n    Hemostatic Effects of Tranexamic Acid in Cesarean Delivery: An Ancillary Study of the TRAAP2 Study.\r\n GFC/LT evidenced fibrinolysis activation during cesarean delivery, linked to a decrease in fibrinolytic inhibitors. GFC/LT revealed a significant antifibrinolytic effect of TXA compared with placebo.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nOf mice and man - The unwinding of CLEC-2 as an anti-thrombotic target?\r\nN/A.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nParenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions.\r\nNovel parenteral antiplatelet drugs, such as cangrelor, selatogrel, and zalunfiban, have been recently developed to achieve rapid, potent antiplatelet effects while preserving hemostasis. We provide a description of currently available parenteral antiplatelet agents and of those in clinical development for prehospital administration in STEMI patients.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProtein Tyrosine Phosphatase 1B Deficiency in Vascular Smooth Muscle Cells Promotes Perivascular Fibrosis following Arterial Injury.\r\n  Chronic reduction of PTP1B in SMCs promotes dedifferentiation, perivascular fibrosis, and adverse remodeling following vascular injury by mechanisms involving an ERK1/2 phosphorylation-driven shift from SMAD2 to KLF4-regulated gene transcription.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nReviews&Editorials\r\nPlenty of the editorials are available as full text through the publisher website using the provided link\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#jdegrcapax .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#jdegrcapax .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#jdegrcapax .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#jdegrcapax .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#jdegrcapax .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#jdegrcapax .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#jdegrcapax .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#jdegrcapax .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#jdegrcapax .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#jdegrcapax .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#jdegrcapax .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#jdegrcapax .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#jdegrcapax .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#jdegrcapax .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#jdegrcapax .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#jdegrcapax .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#jdegrcapax .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#jdegrcapax .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#jdegrcapax .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#jdegrcapax .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#jdegrcapax .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#jdegrcapax .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#jdegrcapax .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#jdegrcapax .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#jdegrcapax .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#jdegrcapax .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#jdegrcapax .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    HbSC disease: A time for progress.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nAnn Oncol\r\n    Neoadjuvant immunotherapy in TNBC: lesson learnt, remaining questions.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood\r\n    AML relapse after a TIGIT race.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBispecifics need a mindful pause.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nCHIP and gout: trained immunity?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDesmopressin revisited inÂ mild hemophilia A.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDiffuse myocardial fibrosis as an SCD biomarker.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGrab and go: transferrin uptake in erythropoiesis.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIn APL, noncoding mutations and SNP converge on WT1.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMCD-DLBCL arises from germinal center B cells.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMDM2 inhibition augments GVL effect.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nMutant CALR's \"sweet tooth\".\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRadiotherapy is here to stay.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTet2 helps blood cells balance in air.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTranexamic acid as a stopgap for low platelets?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nJ Hematol Oncol\r\n    Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.\r\nAdditionally, stimuli-responsive nanoplatforms have also been considered as a promising and effective targeting strategy against tumors, as these nanoplatforms maintain their stealth feature under normal conditions, but upon homing in on cancerous lesions or their microenvironment, are responsive and release their cargoes. In this review, we comprehensively summarize the field of active targeting drug delivery systems and a number of stimuli-responsive release studies in the context of emerging nanoplatform development, and also discuss how this knowledge can contribute to further improvements in clinical practice.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiquid biopsy: current technology and clinical applications.\r\nIn conclusion, liquid biopsy is a powerful tool, and remarkable advances in this technology have impacted multiple aspects of precision oncology, from early diagnosis to management of refractory metastatic disease. Future research may focus on fluids beyond blood, such as ascites, effusions, urine, and cerebrospinal fluid, as well as methylation patterns and elements such as exosomes.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nNaturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets.\r\ng., 3,10-dibromofascaplysin combined with olaparib) to exhibit therapeutic potential against various cancers by regulating RCD subroutines. In short, the information provided in this review on the regulation of cell death by indole alkaloids against different targets is expected to be beneficial for the design of novel molecules with greater targeting and biological properties, thereby facilitating the development of new strategies for cancer therapy.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThe molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.\r\nIn this review, we described the molecular mechanisms, signaling pathways, and the stages of tumorigenesis involved in the EMT process and discussed the dynamic non-binary process of EMT and its role in tumor metastasis. Finally, we summarized the challenges of chemotherapy and immunotherapy in EMT and proposed strategies for tumor therapy targeting EMT.\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nMiscellaneous\r\nmisc publications eg case reports, tools of the trade, images of the month, etcâ€¦\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#uyzakeqson .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#uyzakeqson .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#uyzakeqson .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#uyzakeqson .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#uyzakeqson .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#uyzakeqson .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#uyzakeqson .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#uyzakeqson .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#uyzakeqson .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#uyzakeqson .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#uyzakeqson .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#uyzakeqson .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#uyzakeqson .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#uyzakeqson .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#uyzakeqson .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#uyzakeqson .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#uyzakeqson .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#uyzakeqson .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#uyzakeqson .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#uyzakeqson .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#uyzakeqson .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#uyzakeqson .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#uyzakeqson .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#uyzakeqson .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#uyzakeqson .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#uyzakeqson .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#uyzakeqson .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Blood\r\n    Clonal Hematopoiesis of Indeterminate Potential and Risk of Death from COVID-19.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nDuault C, Kumar A, Taghi Khani A, etÂ al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021;138(16):1465-1480.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nGelatinous transformation of bone marrow and concomitant fungal infection in a patient with HIV.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIntroduction to the How I Treat Series on \"How I Manage High-Risk Patients Following Allogeneic Transplant\".\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nProgression of CCND1- in situ mantle cell neoplasia to CCND1- mantle cell lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRisk Factors for Severe Infection and Mortality in COVID-19 and Monoclonal Gammopathy of Undetermined Significance.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSadler B, Christopherson PA, Haller G, Montgomery RR, Di Paola J; Zimmerman Program Investigators. von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene. Blood. 2021;137(23):3277-3283.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSingle Cell Genomics - a new chapter in how technological advances propel Hemato-Oncology.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nTumburu L, Ghosh-Choudhary S, Seifuddin FT, etÂ al. Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease. Blood. 2021;137(22):3116-3126.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Adv\r\n    Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nFirst description of the t(3;17)(q27;q21)/IGF2BP2::LSM12 translocation in marginal zone lymphoma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHumoral and Cellular Responses to SARS-CoV-2 Vaccines Before and After Chimeric Antigen Receptor-Modified T Cell Therapy.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIs donor-recipient sex associated with transfusion-related outcomes in critically ill patients?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nRacial and socioeconomic disparities in CLL/SLL: Analysis of SEER data from 2006-2019.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSoluble urokinase-type plasminogen activator receptor in sickle cell disease-associated chronic kidney disease.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nThird-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralisation in patients with chronic myeloid disorders.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nUnder-representation of classical hematology training on hematology-oncology fellowship program websites in the United States.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nYes, donor-recipient sex is associated with transfusion-related outcomes in critically ill patients.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLancet Haematol\r\n    CD19 CAR T cells for infants and young children.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLeukemia\r\n    A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIs unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\nLetters&Replies\r\nLetters to the editors and authorsâ€™ replies\r\n\r\nhtml {\r\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\r\n}\r\n\r\n#akveokxpxy .gt_table {\r\n  display: table;\r\n  border-collapse: collapse;\r\n  margin-left: auto;\r\n  margin-right: auto;\r\n  color: #333333;\r\n  font-size: 16px;\r\n  font-weight: normal;\r\n  font-style: normal;\r\n  background-color: #FFFFFF;\r\n  width: auto;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #A8A8A8;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #A8A8A8;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_heading {\r\n  background-color: #FFFFFF;\r\n  text-align: center;\r\n  border-bottom-color: #FFFFFF;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_title {\r\n  color: #333333;\r\n  font-size: 125%;\r\n  font-weight: initial;\r\n  padding-top: 4px;\r\n  padding-bottom: 4px;\r\n  border-bottom-color: #FFFFFF;\r\n  border-bottom-width: 0;\r\n}\r\n\r\n#akveokxpxy .gt_subtitle {\r\n  color: #333333;\r\n  font-size: 85%;\r\n  font-weight: initial;\r\n  padding-top: 0;\r\n  padding-bottom: 6px;\r\n  border-top-color: #FFFFFF;\r\n  border-top-width: 0;\r\n}\r\n\r\n#akveokxpxy .gt_bottom_border {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_col_headings {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_col_heading {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 6px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#akveokxpxy .gt_column_spanner_outer {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: normal;\r\n  text-transform: inherit;\r\n  padding-top: 0;\r\n  padding-bottom: 0;\r\n  padding-left: 4px;\r\n  padding-right: 4px;\r\n}\r\n\r\n#akveokxpxy .gt_column_spanner_outer:first-child {\r\n  padding-left: 0;\r\n}\r\n\r\n#akveokxpxy .gt_column_spanner_outer:last-child {\r\n  padding-right: 0;\r\n}\r\n\r\n#akveokxpxy .gt_column_spanner {\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: bottom;\r\n  padding-top: 5px;\r\n  padding-bottom: 5px;\r\n  overflow-x: hidden;\r\n  display: inline-block;\r\n  width: 100%;\r\n}\r\n\r\n#akveokxpxy .gt_group_heading {\r\n  padding: 8px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#akveokxpxy .gt_empty_group_heading {\r\n  padding: 0.5px;\r\n  color: #333333;\r\n  background-color: #94D4F5;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  vertical-align: middle;\r\n}\r\n\r\n#akveokxpxy .gt_from_md > :first-child {\r\n  margin-top: 0;\r\n}\r\n\r\n#akveokxpxy .gt_from_md > :last-child {\r\n  margin-bottom: 0;\r\n}\r\n\r\n#akveokxpxy .gt_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  margin: 10px;\r\n  border-top-style: solid;\r\n  border-top-width: 1px;\r\n  border-top-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 1px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 1px;\r\n  border-right-color: #D3D3D3;\r\n  vertical-align: middle;\r\n  overflow-x: hidden;\r\n}\r\n\r\n#akveokxpxy .gt_stub {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  font-size: 100%;\r\n  font-weight: initial;\r\n  text-transform: inherit;\r\n  border-right-style: solid;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n  padding-left: 12px;\r\n}\r\n\r\n#akveokxpxy .gt_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#akveokxpxy .gt_first_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_grand_summary_row {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  text-transform: inherit;\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n}\r\n\r\n#akveokxpxy .gt_first_grand_summary_row {\r\n  padding-top: 8px;\r\n  padding-bottom: 8px;\r\n  padding-left: 5px;\r\n  padding-right: 5px;\r\n  border-top-style: double;\r\n  border-top-width: 6px;\r\n  border-top-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_striped {\r\n  background-color: rgba(128, 128, 128, 0.05);\r\n}\r\n\r\n#akveokxpxy .gt_table_body {\r\n  border-top-style: solid;\r\n  border-top-width: 2px;\r\n  border-top-color: #D3D3D3;\r\n  border-bottom-style: solid;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_footnotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_footnote {\r\n  margin: 0px;\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#akveokxpxy .gt_sourcenotes {\r\n  color: #333333;\r\n  background-color: #FFFFFF;\r\n  border-bottom-style: none;\r\n  border-bottom-width: 2px;\r\n  border-bottom-color: #D3D3D3;\r\n  border-left-style: none;\r\n  border-left-width: 2px;\r\n  border-left-color: #D3D3D3;\r\n  border-right-style: none;\r\n  border-right-width: 2px;\r\n  border-right-color: #D3D3D3;\r\n}\r\n\r\n#akveokxpxy .gt_sourcenote {\r\n  font-size: 90%;\r\n  padding: 4px;\r\n}\r\n\r\n#akveokxpxy .gt_left {\r\n  text-align: left;\r\n}\r\n\r\n#akveokxpxy .gt_center {\r\n  text-align: center;\r\n}\r\n\r\n#akveokxpxy .gt_right {\r\n  text-align: right;\r\n  font-variant-numeric: tabular-nums;\r\n}\r\n\r\n#akveokxpxy .gt_font_normal {\r\n  font-weight: normal;\r\n}\r\n\r\n#akveokxpxy .gt_font_bold {\r\n  font-weight: bold;\r\n}\r\n\r\n#akveokxpxy .gt_font_italic {\r\n  font-style: italic;\r\n}\r\n\r\n#akveokxpxy .gt_super {\r\n  font-size: 65%;\r\n}\r\n\r\n#akveokxpxy .gt_footnote_marks {\r\n  font-style: italic;\r\n  font-weight: normal;\r\n  font-size: 65%;\r\n}\r\n\r\n    Am J Hematol\r\n    Corneal Toxicity with Belantamab mafodotin: Multi-institutional Real-Life Experience.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nHaploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: a retrospective study from the Adult Myelodysplastic Syndrome Working Group of the Japanese Society for Transplantation and Cellular Therapy (JSTCT).\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nIncreased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLiquid biopsies in blood donors: Issues in implementing cell-free DNA cancer screening tests in the blood donor population.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nLong-term outcomes in light chain deposition disease- analysis of a UK cohort.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nSecondary-type mutations do not impact prognosis in AML with mutated NPM1.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\nBlood Cancer J\r\n    Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ  Â PMC\r\nThe prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma.\r\n\r\nPubmedÂ  Â JournalÂ  Â ReadQxÂ \r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n// add bootstrap table styles to pandoc tables\r\nfunction bootstrapStylePandocTables() {\r\n  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');\r\n}\r\n$(document).ready(function () {\r\n  bootstrapStylePandocTables();\r\n});\r\n\r\n\r\n\r\n$(document).ready(function () {\r\n  window.buildTabsets(\"TOC\");\r\n});\r\n\r\n$(document).ready(function () {\r\n  $('.tabset-dropdown > .nav-tabs > li').click(function () {\r\n    $(this).parent().toggleClass('nav-tabs-open');\r\n  });\r\n});\r\n\r\n  (function () {\r\n    var script = document.createElement(\"script\");\r\n    script.type = \"text/javascript\";\r\n    script.src  = \"https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML\";\r\n    document.getElementsByTagName(\"head\")[0].appendChild(script);\r\n  })();\r\n\r\n\r\n\r\n\r\n\r\n",
    "preview": {},
    "last_modified": "2022-09-16T23:52:08-04:00",
    "input_file": {}
  }
]
